Guest Editor(s)
-
- Dr. Vicenç Ruiz de Porras
- Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Ctra. Can Ruti-Camí de les Escoles s/n, Badalona, Spain.
Website | E-mail
Special Issue Introduction
Curcumin - the golden spice - is a hydrophobic polyphenol that constitutes the major curcuminoid in the spice turmeric (77% curcumin, 17% demethoxycurcumin and 3% bis-demethoxycurcumin), and is derived from the rhizome of the herb Curcuma longa. Used for centuries in the Ayurveda medicine, its demonstrated anticancer properties and low toxicity profile made it the focus of hundreds of preclinical and clinical investigations in several tumor types. Many of these anti-tumoral properties have been attributed to its role as an anti-inflammatory and anti-oxidant, or its ability to modulate the cell cycle and pathways involved in proliferation, apoptosis, migration, invasion, angiogenesis and metastasis. So far, we know that it can be combined with several anti-cancer agents in a safe and synergistic way, thereby overcoming drug resistance. Regretfully, its poor bioavailability has been one of the main issues for its successful introduction in the clinic. Nevertheless, a plethora of new formulations with a huge increase in bioavailability are under study with promising results.
This Special Issue of Cancer Drug Resistance, therefore, encompasses original and review articles on the molecular mechanisms of action of curcumin to overcome anti-tumoral therapy resistance, novel curcumin-based therapeutic strategies, new clinical approaches, as well as new biomarkers predicting response to curcumin treatment.
Submission Deadline
31 Oct 2022
Cancer Drug Resistance
